文献速递肾癌与肾肿瘤

联合免疫治疗时代接受延期、前期或不接受减瘤性肾切除术的转移性肾细胞癌患者特征:国际转移性肾细胞癌数据库联盟结果

Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
PubMed 文献 · Eur Urol Oncol · 2023-10-31

基于国际转移性肾细胞癌数据库联盟(IMDC),纳入385例接受一线免疫肿瘤联合治疗的转移性肾细胞癌患者,按减瘤性肾切除术(CN)状态分组。多因素分析显示接受CN为独立有利预后因素(HR 0.45,95%CI 0.26-0.78;P=0.005)。研究因缺乏随机化及回顾性性质受限。

要点

  • 385例中延期CN 24例、前期CN 182例、未行CN 179例。
  • 未行CN组年龄更大、骨转移比例更高,前期CN组IMDC不良风险比例更低。
  • 多因素分析显示接受CN为独立有利预后因素(HR 0.45,95%CI 0.26-0.78;P=0.005)。

核心结论

  • 尽管新型治疗药物出现改变了实践模式,CN在精心选择的患者中仍可能作为有效的手术干预。

研究设计与样本

  • 利用国际转移性肾细胞癌数据库联盟(IMDC)纳入接受一线免疫肿瘤联合治疗的转移性肾细胞癌患者。
  • 前期CN定义为转移性疾病诊断前3个月内但全身治疗开始前进行的CN。
  • 延期CN定义为全身治疗开始后进行的CN。
  • 385例患者符合12个月界标分析条件。

主要发现

  • 385例中行延期CN 24例、前期CN 182例、未行CN 179例。
  • 未行CN组年龄63岁 vs 延期CN组57岁 vs 前期CN组60岁(P=0.001)。
  • 未行CN组骨转移比例44% vs 延期CN组26% vs 前期CN组23%(P<0.001)。
  • 前期CN组IMDC不良风险比例23% vs 未行CN组43% vs 延期CN组47%(P<0.001)。
  • 多因素分析显示接受CN为独立有利预后因素(HR 0.45,95%CI 0.26-0.78;P=0.005)。

临床怎么用

  • 作者认为,尽管实践模式随新型治疗药物出现而改变,CN在精心选择的患者中仍可能作为有效的手术干预。

局限性

  • 研究缺乏随机化。
  • 研究为回顾性性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of cytoreductive nephrectomy (CN) has not yet been well characterized in the era of combination immunotherapy. OBJECTIVE: To evaluate characteristics and outcomes for patients with metastatic renal cell carcinoma (mRCC) who received immuno-oncology (IO)-based combination therapy according to CN status. DESIGN, SETTING, AND PARTICIPANTS: Using the International mRCC Database Consortium (IMDC), patients with mRCC who received frontline IO-based combinations were included. Upfront CN was defined as CN up to 3 mo before diagnosis of metastatic disease but before systemic therapy initiation. Deferred CN was defined as CN after systemic therapy initiation. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) from initiation of systemic therapy was estimated via Cox proportional-hazards regression. A 12-mo landmark time and a time-varying covariate for CN status were used to mitigate potential bias. RESULTS AND LIMITATIONS: Of the 385 patients eligible for landmark analysis, 24, 182, and 179 underwent deferred CN, upfront CN, and no CN, respectively. Patients in the no CN subgroup were older (63 yr vs 57 yr in the deferred CN subgroup and 60 yr in the upfront CN subgroup; p = 0.001) and a higher proportion had bone metastases (44% vs 26% in the deferred CN subgroup and 23% in the upfront CN subgroup; p < 0.001). A lower proportion of patients in the upfront CN subgroup had IMDC poor risk (23% vs 43% in the no CN subgroup and 47% in the deferred CN subgroup; p < 0.001). On multivariable analysis, CN receipt was an independent favorable prognostic factor (hazard ratio 0.45, 95% confidence interval 0.26-0.78; p = 0.005). The study is limited by the lack of randomization and its retrospective nature. CONCLUSIONS: Despite changes in practice patterns with the advent of novel therapeutic agents, CN may still serve as an effective surgical intervention in carefully selected patients. PATIENT SUMMARY: For patients with metastatic kidney cancer, surgery to remove the primary tumor was traditionally the treatment of choice, but immunotherapy drugs are now another option for these patients. We analyzed data for contemporary patients with metastatic kidney cancer who received combination immunotherapy as their first treatment. We found that in selected patients receiving immunotherapy, surgery to remove the primary tumor as well can result in better prognosis.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Takemura K, Ernst MS, Navani V, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2023. PMID: 37914579. doi:10.1016/j.euo.2023.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。